ZYME Archives - BioTuesdays

Developments

Zymeworks announces first patient dosed in Phase 1 trial of ZW171 in cancer

Zymeworks (NASDAQ:ZYME) has announced that the first patient has been dosed in its global first-in-human Phase 1 clinical study to evaluate the safety and tolerability of ZW171 for the treatment of ovarian cancer, non...

October 21, 2024

Developments

Jazz, Zymeworks present positive pivotal data in BTC

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific...

June 5, 2023

Developments

Jazz, Zymeworks post positive Phase 2 survival in metastatic gastroesophageal adenocarcinoma

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) reported the first overall survival (OS) data from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in...

January 19, 2023

Developments

Zymeworks posts positive pivotal topline data in BTC

Zymeworks (NASDAQ ZYME) reported positive topline results from the pivotal Phase 2b HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in...

December 19, 2022

Developments

Jazz Pharma in license for Zymeworks’ HER2 zanidatamab

Jazz Pharmaceuticals (NASDAQ:JAZZ) inked an exclusive licensing agreement to acquire development and commercialization rights to Zymeworks’ (NYSE:ZYME) zanidatamab across all indications in the United States, Europe...

October 19, 2022

Feature

Zymeworks targeting cancer with next-gen multifunctional biotherapeutics

Zymeworks (NYSE:ZYME) is leading a paradigm shift developing next-generation multifunctional antibodies and antibody drug conjugates, with an initial focus on HER2-targeted therapies to treat cancer.

August 16, 2022

Markets

SVB Leerink ups Zymeworks to OP from MP

SVB Leerink upgraded Zymeworks (NYSE:ZYME) to “outperform” from “market perform,” citing a sell-off in the stock that “makes us more constructive, despite some uncertainties.” The stock closed at $16.12 on Dec. 9...

December 10, 2021

Feature

Zymeworks platforms validated by pharma partnerships

By Len Zehr Ali Tehrani, President and CEO Zymeworks’ (NYSE, TSX:ZYME) marquee partnerships with Merck, Eli Lilly, Celgene, GlaxoSmithKline and Daiichi-Sankyo provide validation for its next-generation oncology...

August 29, 2017

Tag - ZYME

Zymeworks announces first patient dosed in Phase 1 trial of ZW171 in cancer

Jazz, Zymeworks present positive pivotal data in BTC

Jazz, Zymeworks post positive Phase 2 survival in metastatic gastroesophageal adenocarcinoma

Zymeworks posts positive pivotal topline data in BTC

Jazz Pharma in license for Zymeworks’ HER2 zanidatamab

Zymeworks targeting cancer with next-gen multifunctional biotherapeutics

SVB Leerink ups Zymeworks to OP from MP

Zymeworks platforms validated by pharma partnerships

Subscribe